Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 996 Kami-Okubo, Sakura-Ku, Saitama,338-0824,japan
- Industry
- Biotechnology
- Website
- https://www.epsilon-mol.co.jp/
- Keywords
- Koganei.
- HQ
- Saitama
Epsilon Molecular Engineering Inc. Questions
Epsilon Molecular Engineering Inc.'s website is https://www.epsilon-mol.co.jp/
Epsilon Molecular Engineering Inc.'s LinkedIn profile is https://jp.linkedin.com/company/epsilon-molecular-engineering-inc
Epsilon Molecular Engineering Inc. has
6 employees.
View email and phone details for 6
employees at Epsilon Molecular Engineering Inc..
Epsilon Molecular Engineering Inc.'s industry is
Biotechnology
Epsilon Molecular Engineering Inc.'s top competitors are
Parexel,
Kishida Chemical,
Nict,
W. L. Gore & Associates,
Chinese Antibody Society,
Veritas In Silico Inc.,
Jd Bioscience,
デンカ（株）.
Epsilon Molecular Engineering Inc.'s categories are Biotechnology
Epsilon Molecular Engineering Inc.'s founding year is 2016
